NASDAQ$SGMT
Sagimet Biosciences Inc-A · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported third quarter 2024 financial results and provided corporate updates.
Sagimet Biosciences reported its Q3 2024 financial results, highlighting the Breakthrough Therapy designation from the FDA for denifanstat in MASH and the anticipated initiation of a Phase 3 program by the end of 2024. The company's cash runway is expected to last through 2025, with cash, cash equivalents, and marketable securities totaling $170.0 million as of September 30, 2024.
- Denifanstat received Breakthrough Therapy designation from the FDA for MASH.
- Phase 2b FASCINATE-2 study results of denifanstat were published in The Lancet Gastroenterology & Hepatology.
- Sagimet completed end-of-Phase 2 interactions with the FDA on the development of denifanstat for MASH, with Phase 3 program initiation expected by the end of 2024.
- The company anticipates a cash runway through 2025, with $170.0 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
Headline financials
Revenue & EPS history
Sagimet Biosciences · Revenue · Quarterly
$2M
Forward guidance
Sagimet Biosciences is focused on advancing denifanstat towards a pivotal Phase 3 program in MASH by the end of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q3 2024
-3.0%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+17.0%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+16.0%
Q4 2023
Best reaction
-21.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -0.2% | -10.2% | -16.5% | |
| Q3 2025 | -12.5% | -11.3% | -29.4% | |
| Q1 2025 | +6.6% | +7.1% | +118.6% | |
| Q4 2024 | +3.5% | -7.0% | -30.5% | |
| Q3 2024 | -21.4% | -26.7% | -27.1% | |
| Q2 2024 | +3.8% | +6.0% | +39.8% | |
| Q1 2024 | +8.4% | +8.2% | -5.5% | |
| Q1 2023 | +8.4% | +8.2% | -5.5% | |
| Q4 2023 | +16.0% | +20.2% | -7.5% | |
| Q3 2022 | -2.5% | +14.5% | +113.9% | |
| Q3 2023 | -2.5% | +14.5% | +113.9% | |
| Q2 2022 | -16.3% | -5.1% | -8.6% | |
| Q2 2023 | -16.3% | -5.1% | -8.6% | |
| Q4 2022 | -16.3% | -5.1% | -8.6% | |
| Q1 2022 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro